These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 33989278)

  • 1. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
    Steiner M; Tan AR
    Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
    Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
    Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
    Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
    Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis.
    Xin Y; Shen G; Zheng Y; Guan Y; Huo X; Li J; Ren D; Zhao F; Liu Z; Li Z; Zhao J
    BMC Cancer; 2021 Nov; 21(1):1261. PubMed ID: 34814874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
    Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H
    J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer.
    Zhu H; Du C; Yuan M; Fu P; He Q; Yang B; Cao J
    Drug Discov Today; 2020 Sep; 25(9):1762-1771. PubMed ID: 32663441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current usage of pembrolizumab in triple negative breast cancer (TNBC).
    O'Rourke H; Hart C; De Boer RH
    Expert Rev Anticancer Ther; 2024 May; 24(5):253-261. PubMed ID: 38594892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Immunotherapy in Breast Cancer.
    Jacob SL; Huppert LA; Rugo HS
    JCO Oncol Pract; 2023 Apr; 19(4):167-179. PubMed ID: 36608303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments.
    Rayson VC; Harris MA; Savas P; Hun ML; Virassamy B; Salgado R; Loi S
    Trends Cancer; 2024 Jun; 10(6):490-506. PubMed ID: 38521654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint blockade in the treatment of breast cancer: current status and future directions.
    Wein L; Luen SJ; Savas P; Salgado R; Loi S
    Br J Cancer; 2018 Jul; 119(1):4-11. PubMed ID: 29808015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Immunotherapy in Triple-Negative Breast Cancer.
    Keenan TE; Tolaney SM
    J Natl Compr Canc Netw; 2020 Apr; 18(4):479-489. PubMed ID: 32259782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis.
    Villacampa G; Navarro V; Matikas A; Ribeiro JM; Schettini F; Tolosa P; Martínez-Sáez O; Sánchez-Bayona R; Ferrero-Cafiero JM; Salvador F; Papakonstantinou A; Prat A; Oliveira M; Pascual T
    JAMA Oncol; 2024 Oct; 10(10):1331-1341. PubMed ID: 39207778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    Sternschuss M; Yerushalmi R; Saleh RR; Amir E; Goldvaser H
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3369-3379. PubMed ID: 33745080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment.
    O'Connell BC; Hubbard C; Zizlsperger N; Fitzgerald D; Kutok JL; Varner J; Ilaria R; Cobleigh MA; Juric D; Tkaczuk KHR; Elias A; Lee A; Dakhil S; Hamilton E; Soliman H; Peluso S
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39214650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
    Varma R; Wright M; Abraham J; Kruse M
    Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of PD-L1 using SP142 CDx in triple negative breast cancer.
    Al-Jussani GN; Dabbagh TZ; Al-Rimawi D; Sughayer MA
    Ann Diagn Pathol; 2021 Apr; 51():151703. PubMed ID: 33454500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Mutational Burden and
    Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM
    Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.